100-year-old scientific mystery solved: Researchers discover role of nuclear glycogen in non-small cell lung cancers

Researchers at the University of Kentucky Markey Cancer Center have made a breakthrough discovery that solves a mystery long forgotten by science and have identified a potentially novel avenue in pre-clinical models to treat non-small cell lung cancers. Published in Cell Metabolism, the research centers on the function of glycogen accumulation in the nucleus of a cell. Glycogen is known […]

Continue reading »

Brigatinib becomes potential new first-line option for ALK-positive non-small lung cancer

Results of a 275-patient, multi-national phase III clinical trial known as ALTA-1L published today in the New England Journal of Medicine and presented concurrently in the press program at the International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer 2018 argue for brigatinib as a first-line treatment option for advanced ALK-positive non-small cell lung cancer. […]

Continue reading »